{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:03:15Z","timestamp":1782741795825,"version":"3.54.5"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pexidartinib (Turalio) is the only systemic therapy approved by the United States Food and Drug Administration for the treatment of patients with tenosynovial giant cell tumors (TGCT ) based on clinical benefits demonstrated in the Phase III ENLIVEN trial. The present study assessed longitudinal patient-reported outcomes of patients treated with pexidartinib for TGCT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A longitudinal study was conducted in adult patients who received pexidartinib via the Risk Evaluation and Mitigation Strategy in the United States. Two web-based surveys containing patient-reported outcome questionnaires were administered to eligible patients (at least 18 years of age, had taken at least 1 dose of pexidartinib before baseline survey and still on treatment with pexidartinib at the time of follow-up survey, had not participated in any clinical trials for pexidartinib, and could complete questionnaires in English). The first assessment was initiated in 2021 (baseline), and the second was completed in 2022-2023 (follow-up).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 83 eligible patients who completed baseline assessment, 45 were eligible for follow-up. Thirty-one of whom consented and 28 completed the assessment. At the time of the follow-up survey, the mean (range) treatment duration was 18.5 (10.6-36.2) months, mean (SD) age was 41.9 (13.70) years, and 67.7% of the patients were female. The most common tumor sites were in the knee (67.7%) and ankle (16.1%). At follow-up, over 85% of patients reported symptom improvement since initiation of treatment with pexidartinib, and nearly 70% of patients reported symptoms to be \u201cVery much improved\u201d or \u201cMuch improved.\u201d From baseline to follow-up assessment, changes in patient-reported measures on physical function, pain, and stiffness were not statistically significant (P\u2005&amp;gt;\u2005.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Findings from this longitudinal study showed continued benefit of pexidartinib in overall symptom improvement from patients\u2019 perspectives after an additional year of continued use among patients with symptomatic TGCT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf028","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:23:03Z","timestamp":1743459783000},"source":"Crossref","is-referenced-by-count":3,"title":["Patient-reported continued benefits of pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0231-1422","authenticated-orcid":false,"given":"Dong","family":"Dai","sequence":"first","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ 07920 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pan","sequence":"additional","affiliation":[{"name":"United BioSource LLC , Blue Bell, PA 19422 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Freivogel","sequence":"additional","affiliation":[{"name":"United BioSource LLC , Blue Bell, PA 19422 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ 07920 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Tecson","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ 07920 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tap","sequence":"additional","affiliation":[{"name":"Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"2025033118435150800_CIT0001","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025033118435150800_CIT0002","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"key":"2025033118435150800_CIT0003","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"key":"2025033118435150800_CIT0004","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","article-title":"Patient-reported symptoms of tenosynovial giant cell tumors","volume":"38","author":"Gelhorn","year":"2016","journal-title":"Clin Ther"},{"key":"2025033118435150800_CIT0005","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2196\/ijmr.9325","article-title":"The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life","volume":"7","author":"Mastboom","year":"2018","journal-title":"Inter J Med Res"},{"key":"2025033118435150800_CIT0006","volume-title":"Package Insert","author":"Turalio","year":"2025"},{"key":"2025033118435150800_CIT0007","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"2025033118435150800_CIT0008","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17453674.2021.1922161","article-title":"Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial","volume":"92","author":"Van De Sande","year":"2021","journal-title":"Acta Orthop."},{"key":"2025033118435150800_CIT0009","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CORR.0000000000002335","article-title":"Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: results from ENLIVEN","volume":"481","author":"Healey","year":"2022","journal-title":"Clin Orthop Relat Res"},{"key":"2025033118435150800_CIT0010","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1093\/oncolo\/oyad282","article-title":"Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor","volume":"29","author":"Lin","year":"2023","journal-title":"Oncologist"},{"key":"2025033118435150800_CIT0011","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41687-019-0099-0","article-title":"The measurement of physical functioning among patients with tenosynovial giant cell tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"3","author":"Gelhorn","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"2025033118435150800_CIT0012","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-020-0181-7","article-title":"Development and validation of an interpretive guide for PROMIS scores","volume":"4","author":"Rothrock","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2025033118435150800_CIT0013","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"2025033118435150800_CIT0014","author":"Guy","year":"1976","journal-title":"ECDEU Assessment Manual for Psychopharmacology"},{"key":"2025033118435150800_CIT0015","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2007","journal-title":"J Pain"},{"key":"2025033118435150800_CIT0016","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41687-020-00217-6","article-title":"Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors","volume":"4","author":"Speck","year":"2020","journal-title":"J Patient Rep Outcomes"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf028\/62820296\/oyaf028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf028\/62820296\/oyaf028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:23:18Z","timestamp":1743459798000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf028\/8101337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf028","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyaf028"}}